References
- Vaccines against influenza: WHO position paper – May 2022. [accessed 2022 Sep 15]. https://www.who.int/publications/i/item/who-wer9719.
- Putri WCWS, Muscatello DJ, Stockwell MS, Newall AT. Economic burden of seasonal influenza in the United States. Vaccine. 2018;36(27):3960–5. doi:10.1016/j.vaccine.2018.05.057.
- Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother. 1999;44(Suppl B):11–15. doi:10.1093/jac/44.suppl_2.11.
- Tyrrell CS, Allen JLY, Gkrania-Klotsas E. Influenza: epidemiology and hospital management. Medicine (Abingdon). 2021;49(12):797–804. doi:10.1016/j.mpmed.2021.09.015.
- Paget J, Danielle Iuliano A, Taylor RJ, Simonsen L, Viboud C, Spreeuwenberg P. Global seasonal influenza-associated mortality collaborator network and GLaMOR collaborating teams. Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR project. Vaccine. 2022;40(9):1361–9. doi:10.1016/j.vaccine.2021.11.080.
- Gasparini R, Amicizia D, Lai PL, Panatto D. Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly. Hum Vaccin Immunother. 2012;8(1):21–28. doi:10.4161/hv.8.1.17622.
- Fallani E, Orsi A, Signori A, Icardi G, Domnich A. An exploratory study to assess patterns of influenza- and pneumonia-related mortality among the Italian elderly. Hum Vaccin Immunother. 2021;17(12):5514–21. doi:10.1080/21645515.2021.2005381.
- Panatto D, Gasparini R, Amicizia D. Influenza vaccination coverage in the elderly and socio-economic inequalities in Italy. J Prev Med Hyg. 2019;59(4 Suppl 2):E1–E2. doi:10.15167/2421-4248/jpmh2018.59.4s2.1198.
- Gasparini R, Amicizia D, Lai PL, Panatto D. Influenza vaccination: from epidemiological aspects and advances in research to dissent and vaccination policies. J Prev Med Hyg. 2016;57:E1–E4.
- Trucchi C, Paganino C, Orsi A, Amicizia D, Tisa V, Piazza MF, Gallo D, Simonetti S, Buonopane B, Icardi G, et al. Hospital and economic burden of influenza-like illness and lower respiratory tract infection in adults ≥50 years-old. BMC Health Serv Res. 2019;19(1):585. doi:10.1186/s12913-019-4412-7.
- European Centre for Disease Prevention and Control. Seasonal influenza. [accessed 2022 Sep 13]. https://www.ecdc.europa.eu/en/seasonal-influenza.
- WHO Global Influenza Programme. [accessed 2023 Jan 30]. https://www.who.int/teams/global-influenza-programme/vaccines.
- ECDC. Seasonal influenza vaccination strategies. [accessed 2023 Jan 30]. https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/vaccination-strategies.
- Dos Santos G. Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives. Hum Vaccin Immunother. 2019;15(11):2624–36. doi:10.1080/21645515.2019.1608745.
- Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, Morgan RL, Fry AM. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2022–23 Influenza Season. MMWR Recomm Rep. 2022 Aug 26;71(1):1–28. doi:10.15585/mmwr.rr7101a1.
- European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC). [accessed 2023 Sep 13]. https://www.ema.europa.eu/en/glossary/prac.
- European Medicines Agency (EMA). Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. [accessed 2022 Sep 13]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165492.pdf.
- European Medicines Agency (EMA). Fluad Tetra. [accessed 2022 Sep 15]. https://www.ema.europa.eu/en/documents/product-information/fluad-tetra-epar-product-information_en.pdf.
- Italian Medicine Agency. Fluad, summary of product characteristics. [accessed 2022 Sep 15]. https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004166_031840_RCP.pdf&retry=0&sys=m0b1l3.
- de Waure C, Boccalini S, Bonanni P, Amicizia D, Poscia A, Bechini A, Barbieri M, Capri S, Specchia ML, Di Pietro ML, et al. Adjuvanted influenza vaccine for the Italian elderly in the 2018/19 season: an updated health technology assessment. Eur J Public Health. 2019;29(5):900–5. doi:10.1093/eurpub/ckz041.
- Calabrò GE, Boccalini S, Panatto D, Rizzo C, Di Pietro ML, Abreha FM, Ajelli M, Amicizia D, Bechini A, Giacchetta I, et al. The new quadrivalent adjuvanted influenza vaccine for the Italian elderly: a health technology assessment. Int J Environ Res Public Health. 2022;19(7):4166. doi:10.3390/ijerph19074166.
- Domnich A, Arata L, Amicizia D, Puig-Barberà J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: a systematic review and meta-analysis. Vaccine. 2017;35(4):513–20. doi:10.1016/j.vaccine.2016.12.011.
- Barbieri M, Capri S, Waure C, Boccalini S, Panatto D. Age- and risk-related appropriateness of the use of available influenza vaccines in the Italian elderly population is advantageous: results from a budget impact analysis. J Prev Med Hyg. 2017;58(4):E279–87. doi:10.15167/2421-4248/jpmh2017.58.4.867.
- Panatto D, Haag M, Lai PL, Tomczyk S, Amicizia D, Lino MM. Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59® -adjuvanted influenza vaccine in older adults: results from three consecutive seasons. Influenza Other Respir Viruses. 2020;14(1):61–66. doi:10.1111/irv.12685.
- Vaccine report 2021. The Italian postmarketing surveillance of non covid vaccines. [accessed 2023 Feb 10]. https://www.aifa.gov.it/-/aifa-pubblica-il-rapporto-vaccini-2021-1.
- Haber P, Moro PL, Ng C, Dores GM, Lewis P, Cano M. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016–June 2018. Vaccine. 2019 Mar 7;37(11):1516–20. doi:10.1016/j.vaccine.2019.01.052.
- Yoo BW, Kim CO, Izu A, Arora AK, Heijnen E. Phase 4, post-marketing safety surveillance of the MF59-adjuvanted influenza vaccines FLUAD® and VANTAFLU® in South Korean subjects aged ≥65 years. Infect Chemother. 2018 Dec;50(4):301–10. doi:10.3947/ic.2018.50.4.301.
- Pillsbury AJ, Fathima P, Quinn HE, Cashman P, Blyth CC, Leeb A, Macartney KK. Comparative postmarket safety profile of adjuvanted and high-dose influenza vaccines in individuals 65 years or older. JAMA Netw Open. 2020 May 1;3(5):e204079. doi:10.1001/jamanetworkopen.2020.4079.
- Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine. 2009;27(49):6959–65. doi:10.1016/j.vaccine.2009.08.101.
- de Lusignan S, Dos Santos G, Byford R, Schuind A, Damaso S, Shende V, McGee C, Yonova I, Ferreira F. Enhanced safety surveillance of seasonal quadrivalent influenza vaccines in English primary care: interim analysis. Adv Ther. 2018;35(8):1199–214. doi:10.1007/s12325-018-0747-4.
- Clothier HJ, Crawford NW, Russell M, Buttery JP. Adverse events following vaccination of older people may be under-reported. Med J Aust. 2017 Sep 2;207(7):301–2. doi:10.5694/mja16.01371.
- Domnich A, Panatto D, Pariani E, Napoli C, Chironna M, Manini I, Rizzo C, Orsi A, Icardi G, IT-BIVE-HOSP Network Study Group. Relative effectiveness of the adjuvanted versus non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults. Int J Infect Dis. 2022;125:164–9. doi:10.1016/j.ijid.2022.10.041.
- WHO. The safety of medicines in public health programmes: pharmacovigilance an essential tool. [accessed 2022 Sep 15]. https://apps.who.int/iris/bitstream/handle/10665/43384/9241593911_eng.pdf.